

HB 2527 -- PRESCRIPTION DRUG COSTS

SPONSOR: Kelley (127)

This bill requires health insurance deductible or coinsurance payments for prescription insulin to be calculated at the point of sale based on a price that is reduced by an amount equal to at least 100% of all rebates received, or to be received, in connection with the dispensing or administration of the drug. The bill does not require any entity to disclose the actual amount of rebates received on a product, manufacturer, or pharmacy-specific basis as it considers that information subject to "trade secret" protections.

This bill is similar to SB 962 (2020).